In a UCB-funded network meta-analysis of 17 trials, bimekizumab ranked first on HiSCR50, HiSCR75, and IHS4-55 among HS drugs at Weeks 12 - 16.
News|Articles|July 22, 2024
The JAK Inhibitors Changing Dermatology
Author(s)Kevin Kunzmann
In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.
Advertisement
Advertisement
Over the last 13 years, 10 separate therapies under the Janus kinase (JAK) inhibitor drug class have received US Food and Drug Administration (FDA) approval. These agents have predominately reached
Related to this article
Mona Shahriari, MD, and Valerie D. Callender, MD, discuss trial diversity, better outcome measures, and how investigators can earn patient trust.
Clinicians at ACAAI 2026 will see late-breaking HAE, anaphylaxis, urticaria, and food allergy data, plus exclusive expert interviews.
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study in > 1000 participants with highly chronic TRD.
The 2027 GOLD report recommends a LAMA for group A, defines 6 pre-COPD types, and expands CT, rehabilitation, and cardiovascular guidance for COPD.
Topline results presented at The Liver Meeting showed 79% of patients with HDV reached undetectable HDV RNA at 48 weeks with monthly elebsiran plus tobevibart.
Kausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.
In the phase 2b IMPACT trial, up to 42.9% of patients with MASH achieved concurrent liver fat, ALT, and stiffness responses on pemvidutide vs 3.3% on placebo.
Advertisement
Advertisement